1. Home
  2. GNW vs ADPT Comparison

GNW vs ADPT Comparison

Compare GNW & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Genworth Financial Inc

GNW

Genworth Financial Inc

HOLD

Current Price

$8.75

Market Cap

3.3B

Sector

Finance

ML Signal

HOLD

Logo Adaptive Biotechnologies Corporation

ADPT

Adaptive Biotechnologies Corporation

HOLD

Current Price

$16.17

Market Cap

2.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GNW
ADPT
Founded
1871
2009
Country
US
US
Employees
N/A
N/A
Industry
Life Insurance
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.3B
2.8B
IPO Year
2004
2019

Fundamental Metrics

Financial Performance
Metric
GNW
ADPT
Price
$8.75
$16.17
Analyst Decision
Buy
Strong Buy
Analyst Count
1
9
Target Price
$10.00
$17.78
AVG Volume (30 Days)
3.2M
1.8M
Earning Date
05-02-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
325.00
30.77
EPS
0.53
N/A
Revenue
$7,295,000,000.00
$178,957,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$23.05
P/E Ratio
$16.73
N/A
Revenue Growth
N/A
5.10
52 Week Low
$5.99
$6.26
52 Week High
$9.28
$20.76

Technical Indicators

Market Signals
Indicator
GNW
ADPT
Relative Strength Index (RSI) 50.14 43.04
Support Level $8.84 $14.85
Resistance Level $9.08 $16.42
Average True Range (ATR) 0.23 1.09
MACD 0.02 -0.17
Stochastic Oscillator 56.32 25.25

Price Performance

Historical Comparison
GNW
ADPT

About GNW Genworth Financial Inc

Genworth Financial Inc is a diversified insurance holding company that provides various mortgage and life insurance products. The company has three main operating business segments: Enact, Life and Annuities segment and Long-Term Care Insurance. The company's product portfolio includes various financial products such as traditional life insurance, mortgage insurance, fixed annuities, and variable annuities. Majority of the revenue is generated by the Enact segment. The company earns maximum of its revenue in the United States.

About ADPT Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).

Share on Social Networks: